|Day Low/High||20.70 / 21.60|
|52 Wk Low/High||27.62 / 50.74|
Shanghai Fosun Pharmaceutical owns 3.85 million shares, according to a 13G filing.
Teva is 'in no shape' to be making acquisitions while Mylan is 'still pretty leveraged,' says Oppenheimer analyst Derek Archila.
It is just not going to get better anytime soon.
Teva's stock is crumbling as another analyst slams it with a downgrade.
Teva said weak U.S. markets and the ongoing political turmoil in Venezuela weighed on the company's second quarter performance.
Impax Laboratories, Akebia Therapeutics and Alder BioPharmaceuticals were among the biotech movers in premarket trading on July 17.
BeiGene and Impax Laboratories were among the biotech movers in premarket trading on July 6.
Adamis Pharmaceuticals, Impax Laboratories and Accorda Therapeutics were among the biotech stock movers in premarket trading on June 16.
Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..
The FDA requested Endo to remove its opioid pain medication from the market, expressing concern that the "benefits of the drug may no longer outweigh its risks."
The addition of Perrigo to the list of generics makers under investigation is more bad news for a sector already under pressure from low prices.
The investigation is in relation to drug pricing in the pharmaceutical industry.
In recent trading, shares of Impax Laboratories Inc have crossed above the average analyst 12-month target price of $12.00, changing hands for $12.70/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
The most recent short interest data has been released for the 03/15/2017 settlement date, which shows a 1,670,394 share decrease in total short interest for Impax Laboratories Inc , to 3,500,878, a decrease of 32.30% since 02/28/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
The company hired Paul Bisaro, former chairman at Allergan, to become CEO as Morgan Stanley helps explore alternatives, including a sale.
Paratek Pharmaceuticals soared while Foamix floundered ahead of market's open.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.